Rallybio pivots to oncology in Avenzo merger and $215M financing

Rallybio said June 1 it has agreed to merge with privately held Avenzo Therapeutics in a reverse-merger style deal that would shift the public company’s focus from rare disease to oncology. The combined company would take the Avenzo Therapeutics name, trade on Nasdaq under the ticker AVZO, and launch with a concurrent $215 million private placement. Pre-transaction Rallybio stockholders are expected to own about 2.8% of the combined company, with Avenzo equityholders and new investors holding the rest, and the deal is expected to close in the fourth quarter of 2026, subject to stockholder approval and SEC filings. (avenzotx.com)

Why it matters: For veterinary professionals, this is mostly a capital markets signal rather than a direct clinical development story. But it’s still worth watching because oncology remains one of the most active areas in both human and companion animal medicine, and this transaction underscores where investor money is still flowing: targeted cancer drugs, antibody-drug conjugates, and next-generation cell-cycle inhibitors. Avenzo brings four clinical-stage oncology assets, while Rallybio brings public-market access after a difficult stretch that included a terminated merger with Candid Therapeutics just weeks earlier. (avenzotx.com)

What to watch: Watch for the Form S-4, Rallybio stockholder vote, and whether Avenzo hits its planned late-2026 and second-half 2026 data milestones after the merger financing closes. (businesswire.com)